Literature DB >> 10610770

COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes.

J Flavigny1, M Souchet, P Sébillon, I Berrebi-Bertrand, B Hainque, A Mallet, A Bril, K Schwartz, L Carrier.   

Abstract

Mutations in human cardiac myosin-binding protein C (cMyBP-C) gene are associated with familial hypertrophic cardiomyopathy (FHC), and most of them are predicted to produce COOH-truncated proteins. To understand the molecular mechanism(s) by which such mutations cause FHC, we analyzed (i) the accumulation of human cMyBP-C mutants in fetal rat cardiomyocytes, and (ii) the protein sequence of the human wild-type (wt) cMyBP-C by hydrophobic cluster analysis with the aim of identifying new putative myosin-binding site(s). Accumulation and sarcomeric localization of the wt protein and of four FHC-mutant cMyBP-Cs (E542Q and three COOH-truncated proteins) were studied in cardiomyocytes by immunostaining and confocal microscopy after transfection with myc-tagged constructs. We found that: (i) 10 % of the cells expressing COOH-truncated mutants exhibit an incorporation into the A-band of the sarcomere without any alteration of the myofibrillar architecture versus 76 % of those expressing the wt or E542Q mutant cMyBP-Cs (p<0.001); (ii) 90 % of the cells expressing the truncated mutants show a diffuse localization of these proteins in the cardiomyocytes, out of which 45 % exhibit a significant alteration of the sarcomeric structure (p<0.0001 versus wt); and (iii) the two shortest mutant cMyBP-Cs accumulate at very low levels in fetal rat cardiomyocytes as compared to the wt (p<0.008). Protein sequence analysis indicated that a 45-residue sequence in the NH2-terminal C0 domain of cMyBP-C exhibits a consistent homology (sequence similarity score of 42 %) with a segment of the NH2-terminal domain of myomesin, another myosin-binding protein. This result suggests that the C0 domain of human cMyBP-C contains a novel putative myosin-binding site that could account for the A-band incorporation of the truncated mutants. In addition, the faint accumulation and the diffuse localization of truncated mutants could probably be explained by a low affinity of the C0 domain for myosin. We conclude that COOH-truncated cMyBP-Cs may act as poison polypeptides that disrupt the myofibrillar architecture and result in the defects observed in FHC. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10610770     DOI: 10.1006/jmbi.1999.3276

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  25 in total

1.  Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.

Authors:  Saskia Schlossarek; Friederike Schuermann; Birgit Geertz; Giulia Mearini; Thomas Eschenhagen; Lucie Carrier
Journal:  J Muscle Res Cell Motil       Date:  2011-11-11       Impact factor: 2.698

2.  Troponin I in the murine myocardium: influence on length-dependent activation and interfilament spacing.

Authors:  John P Konhilas; Thomas C Irving; Beata M Wolska; Eias E Jweied; Anne F Martin; R John Solaro; Pieter P de Tombe
Journal:  J Physiol       Date:  2003-01-24       Impact factor: 5.182

Review 3.  Structure, interactions and function of the N-terminus of cardiac myosin binding protein C (MyBP-C): who does what, with what, and to whom?

Authors:  Mark Pfuhl; Mathias Gautel
Journal:  J Muscle Res Cell Motil       Date:  2012-04-20       Impact factor: 2.698

4.  Cardiac myosin binding protein-C modulates actomyosin binding and kinetics in the in vitro motility assay.

Authors:  Walid Saber; Kelly J Begin; David M Warshaw; Peter VanBuren
Journal:  J Mol Cell Cardiol       Date:  2008-03-29       Impact factor: 5.000

Review 5.  The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy.

Authors:  Lucie Carrier; Saskia Schlossarek; Monte S Willis; Thomas Eschenhagen
Journal:  Cardiovasc Res       Date:  2009-07-17       Impact factor: 10.787

Review 6.  Proteasome dysfunction in cardiomyopathies.

Authors:  Jennifer E Gilda; Aldrin V Gomes
Journal:  J Physiol       Date:  2017-03-16       Impact factor: 5.182

Review 7.  Phosphorylation and function of cardiac myosin binding protein-C in health and disease.

Authors:  David Barefield; Sakthivel Sadayappan
Journal:  J Mol Cell Cardiol       Date:  2009-12-03       Impact factor: 5.000

8.  Screening mutations in myosin binding protein C3 gene in a cohort of patients with Hypertrophic Cardiomyopathy.

Authors:  María Isabel Rodríguez-García; Lorenzo Monserrat; Martín Ortiz; Xusto Fernández; Laura Cazón; Lucía Núñez; Roberto Barriales-Villa; Emilia Maneiro; Elena Veira; Alfonso Castro-Beiras; Manuel Hermida-Prieto
Journal:  BMC Med Genet       Date:  2010-04-30       Impact factor: 2.103

9.  Functional differences between the N-terminal domains of mouse and human myosin binding protein-C.

Authors:  Justin F Shaffer; Peony Wong; Kristina L Bezold; Samantha P Harris
Journal:  J Biomed Biotechnol       Date:  2010-04-07

10.  Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy.

Authors:  Adam S Helms; Frank M Davis; David Coleman; Sarah N Bartolone; Amelia A Glazier; Francis Pagani; Jaime M Yob; Sakthivel Sadayappan; Ellen Pedersen; Robert Lyons; Margaret V Westfall; Richard Jones; Mark W Russell; Sharlene M Day
Journal:  Circ Cardiovasc Genet       Date:  2014-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.